Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Ratio (2016 - 2026)

Intellia Therapeutics has reported Equity Ratio over the past 12 years, most recently at 0.82 for Q1 2026.

  • Quarterly Equity Ratio rose 3.47% to 0.82 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.82 through Mar 2026, up 3.47% year-over-year, with the annual reading at 0.8 for FY2025, 8.9% up from the prior year.
  • Equity Ratio was 0.82 for Q1 2026 at Intellia Therapeutics, up from 0.8 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.84 in Q1 2023 and troughed at 0.73 in Q4 2024.
  • The 5-year median for Equity Ratio is 0.81 (2025), against an average of 0.8.
  • Year-over-year, Equity Ratio rose 9.68% in 2023 and then fell 9.3% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.81 in 2022, then decreased by 0.69% to 0.81 in 2023, then dropped by 9.3% to 0.73 in 2024, then grew by 8.9% to 0.8 in 2025, then grew by 2.64% to 0.82 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Equity Ratio are 0.82 (Q1 2026), 0.8 (Q4 2025), and 0.81 (Q3 2025).